# US 2020/0390706 A1 · Spray-dried pharmaceutical compositions comprising active agent nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390706 A1
- Document ID: US20200390706A1
- Status: Published application
- Kind: A1
- Application number: 16/911,598
- Filed: 2020-06-25
- Published: 2020-12-17
- Earliest claimed: 2013-03-04
- Assignees: Besins Healthcare Luxembourg Sarl
- Applicants: Besins Healthcare Luxembourg SARL
- Inventors: Maynard Emanuel Lichty; Garry T. Gwozdz
- Web page: https://patentgrep.com/patent/US20200390706A1

## CPC

- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0043: {Nose}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1682: {Processes}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/18: Feminine contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 μm, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 μm; at least 50% of the spray-dried particles have a particle size of at least about 15 μm; and at least 90% of the spray-dried particles have a particle size of up to about 55 μm. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A dry powder pharmaceutical composition for transmucosal administration, comprising spray-dried particles consisting of (i) pharmaceutically active agent nanoparticles consisting of pharmaceutically active agent and, optionally, a milling aid, (ii) binder, (iii) a water-insoluble pharmaceutically acceptable carrier selected from water insoluble celluloses and water-insoluble starches, and, optionally, (iv) a milling aid, wherein:
the pharmaceutically active agent is allopregnanolone,
the pharmaceutically active agent nanoparticles are spray-dried onto the carrier from an aqueous suspension comprising the pharmaceutically active agent nanoparticles,
the active agent nanoparticles have an average particle size diameter of less than about 1 μm, and
up to 10% of the spray-dried particles have a particle size of less than 10 μm, at least 50% of the spray-dried particles have a particle size of at least about 15 μm, and at least 90% of the spray-dried particles have a particle size of up to about 55 μm.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the water-insoluble pharmaceutically acceptable carrier is microcrystalline cellulose (MCC).

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the binder is selected from the group consisting of hydroxypropyl methyl cellulose (HPMC) and sodium carboxymethylcellulose (NaCMC).

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein milling aid is present.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the milling aid is selected from the group consisting of polysorbate 20, polysorbate 80, and benzalkonium chloride.

### Claim 26 (depends on 21)

The pharmaceutical composition of claim 21, wherein the active agent constitutes about 40 to about 75 wt. % of the spray-dried particles.

### Claim 27 (depends on 21)

The pharmaceutical composition of claim 21, wherein the carrier constitutes about 25 to about 50 wt. % of the spray-dried particles.

### Claim 28 (depends on 21)

The pharmaceutical composition of claim 21, wherein the binder constitutes about 1 to about 15 wt. % of the spray-dried particles.

### Claim 29 (depends on 24)

The pharmaceutical composition of claim 24, wherein the milling aid constitutes about 0.1 to about 5 wt. % of the spray-dried particles.

### Claim 30 (depends on 21)

The pharmaceutical composition of claim 21, wherein the spray-dried particles consist of about 40 to about 75 wt. % allopregnanolone; about 25 to about 50 wt. % carrier; about 1 to about 15 wt. % binder; and about 0.1 to about 5.0 wt. % milling aid.

### Claim 31 (depends on 21)

The pharmaceutical composition of claim 21, further comprising one or more pharmaceutically acceptable excipients.

### Claim 32 (depends on 21)

The pharmaceutical composition of claim 21, further comprising about 5.0 to 30.0% wt./wt. of microcrystalline cellulose having an average particle size diameter from about 30 to about 150 μm, starch, or a mixture thereof, and about 0.1 to 10% wt./wt. tribasic calcium phosphate.

### Claim 33 (depends on 21)

The pharmaceutical composition of claim 21, wherein greater than 90% of the active agent is released from the composition within 60 minutes, when tested via dissolution testing in accordance with USP Dissolution Apparatus 2-Paddle at 75 RPM, 37° C., in a dissolution medium of 900 ml 1.0% Tween®80 in phosphate buffered saline at pH 7.4.

### Claim 34 (depends on 21)

The pharmaceutical composition of claim 21, wherein the composition comprises spray-dried particles having a particle size of less than 10 μm.

### Claim 35 (depends on 21)

The pharmaceutical composition of claim 21, wherein the water-insoluble carrier is selected from crystalline cellulose, microcrystalline cellulose, cellulose, α-cellulose, and cross-linked sodium carboxymethyl cellulose.

### Claim 36 (depends on 21)

The pharmaceutical composition of claim 21, wherein the water-insoluble carrier is selected from hydroxypropyl starch, carboxymethyl starch, and cross-linked starch.

### Claim 37 (depends on 21)

A method for preparing a dry powder pharmaceutical composition for transmucosal administration according to claim 21, comprising spray-drying an aqueous composition comprising (i) pharmaceutically active agent nanoparticles consisting of pharmaceutically active agent and, optionally, a milling aid, (ii) a binder, (iii) a water-insoluble pharmaceutically acceptable carrier selected from water insoluble celluloses and water-insoluble starches, and, optionally, a (iv) milling aid, to obtain spray-dried particles consisting of said pharmaceutically active agent nanoparticles, binder, water-insoluble pharmaceutically acceptable carrier, and, optionally, milling aid, wherein:
the pharmaceutically active agent is allopregnanolone,
the pharmaceutically active agent nanoparticles are spray-dried onto the carrier from an aqueous suspension comprising the pharmaceutically active agent nanoparticles,
the active agent nanoparticles have an average particle size diameter of less than about 1 μm, and
up to 10% of the spray-dried particles have a particle size of less than 10 μm, at least 50% of the spray-dried particles have a particle size of at least about 15 μm, and at least 90% of the spray-dried particles have a particle size of up to about 55 μm.

### Claim 38 (depends on 38)

The method of claim 38, wherein the water-insoluble carrier is microcrystalline cellulose (MCC), and the binder is selected from the group consisting of hydroxypropyl methyl cellulose (HPMC) and sodium carboxymethylcellulose (NaCMC).

### Claim 39 (depends on 38)

A dry pharmaceutical composition for transmucosal administration, comprising spray-dried particles made by a process according to claim 38.

### Claim 40 (depends on 21)

A method of administering allopregnanolone, comprising transmucosally administering the dry pharmaceutical composition according to claim 21.
